Early identification of thoracic malignancy remains an urgent clinical challenge in preventive oncology and respiratory medicine worldwide. Recently, Danish investigators introduced a blood test-informed lung cancer risk model called the Copenhagen Lung Cancer Risk Model (CPH-Lung). By integrating routine circulating biochemical markers with clinical demographic variables, this innovative model dramatically refines patient risk stratification prior to low-dose computed tomography screening.

Limitations of Current Screening and the Need for a New Lung Cancer Risk Model

Low-dose computed tomography undeniably reduces lung cancer mortality across screened populations by identifying early-stage pulmonary nodules. However, conventional eligibility criteria rely predominantly on chronological age and cumulative smoking pack-years. These narrow guidelines frequently overlook high-risk individuals, particularly light smokers, younger adults, and females who fall outside traditional screening thresholds. Furthermore, existing selection protocols derived from landmark trials such as NLST and NELSON demonstrate suboptimal sensitivity in diverse real-world populations. Consequently, many patients receive diagnoses only at advanced stages when curative interventions remain limited.

To overcome these diagnostic gaps, investigators previously designed multivariable clinical calculators such as the PLCOm2012 risk tool. Although PLCOm2012 improved selection by incorporating personal history and educational attainment, it still relies purely on self-reported clinical metrics. Purely demographic tools miss active biological processes, including persistent systemic inflammation and metabolic dysregulation. Therefore, introducing circulating biochemical biomarkers into an established lung cancer risk model provides an indispensable objective advantage. This comprehensive strategy equips clinicians with actionable risk scores, optimizing referral pathways for chest imaging while minimizing unnecessary procedures.

Development and Design of the Copenhagen Risk Assessment Framework

The CPH-Lung prediction tool was developed using extensive longitudinal data from two major prospective Danish general population cohorts. Specifically, researchers utilized the Copenhagen General Population Study to train their primary six-year risk prediction model. The nested case-control training cohort analyzed clinical demographics and biochemical variables from 689 validated lung cancer cases and 1,924 matched controls, all of whom had a documented history of smoking.

Unlike complex genomic tests that require expensive sequencing platforms, CPH-Lung relies on accessible routine laboratory parameters routinely evaluated in clinical chemistry departments. As a result, healthcare systems can realistically implement these blood measurements within general practice and outpatient clinics without prohibitive laboratory costs. In addition, the algorithm specifically models an individual’s personal six-year probability of developing primary thoracic neoplasms. By quantifying systemic inflammatory markers and metabolic variables alongside tobacco exposure, CPH-Lung captures early oncogenic changes long before structural nodules become visible on radiological imaging. Consequently, this multi-modal tool creates a seamless bridge between primary biochemical assessment and targeted diagnostic surveillance.

Validation Findings Demonstrating Superior Discrimination Over Standard Models

External validation in an independent general population confirmed the diagnostic accuracy of the Copenhagen tool. Specifically, investigators tested the algorithm within the prospective Copenhagen City Heart Study, evaluating 3,195 ever-smokers aged fifty years and older. Over six years of continuous clinical monitoring, 68 participants developed confirmed primary lung cancers.

When evaluated against the validated PLCOm2012 model, CPH-Lung demonstrated significantly superior discriminatory capability. Specifically, CPH-Lung achieved an area under the receiver operating characteristic curve of 0.783, compared to 0.720 for PLCOm2012. This notable statistical difference yielded a highly favorable P-value of .0059. Furthermore, researchers observed identical discriminatory advantages within the primary training cohort. These robust metrics prove that circulating biochemical variables contribute substantial predictive value beyond standard clinical metrics alone. Therefore, pairing laboratory data with patient history produces a significantly sharper discrimination profile. As a result, clinicians can identify vulnerable candidates with far greater diagnostic certainty.

Eliminating Screening Disparities Among Women and Younger Populations

A pivotal clinical strength of the CPH-Lung algorithm lies in its ability to resolve persistent sex-specific screening disparities. Historically, clinical selection criteria underperform in females because women frequently develop adenocarcinoma despite lower cumulative tobacco exposure. When investigators benchmarked specificity at 77.7% to mirror standard clinical screening trials, CPH-Lung produced dramatic sensitivity improvements across demographics.

Among female participants, screening sensitivity rose to 57.6% under CPH-Lung, compared to only 39.2% using PLCOm2012. This remarkable 18.4% absolute improvement proved highly significant with a P-value below .0001. Similarly, male participants experienced notable diagnostic gains, with sensitivity increasing from 54.7% to 61.4%. Furthermore, the model substantially improved early detection in younger cohorts. Individuals identified exclusively by CPH-Lung had an average diagnostic age of 68.2 years, compared to 76.5 years for PLCOm2012. Consequently, CPH-Lung captures high-risk disease over eight years earlier, when patients remain prime candidates for curative surgical resections and curative thoracic radiotherapy.

Translational Utility and Implementation Strategies in Clinical Practice

The introduction of blood-informed risk assessment holds profound implications for everyday clinical decision-making. In routine practice, primary care physicians and pulmonologists frequently encounter patients with ambiguous smoking histories or moderate pack-year metrics. Because rigid trial guidelines enforce arbitrary cutoffs, practitioners often face difficult dilemmas regarding whether to order low-dose computed tomography scans. Integrating routine blood tests eliminates this guesswork by delivering objective, individualized risk predictions based on active physiology.

Moreover, incorporating this model into electronic medical records allows automated screening prompts during annual preventive consultations. In resource-constrained healthcare environments, low-dose computed tomography capacity is often severely limited and costly. Therefore, utilizing accessible serum biomarkers as a preliminary triaging mechanism optimizes high-value imaging resources and spares low-risk patients from unnecessary ionizing radiation. While future prospective trials must confirm generalizability across diverse global cohorts, CPH-Lung establishes an invaluable blueprint for precision preventive pulmonology and risk-adapted oncology.

How does the CPH-Lung model differ from conventional risk tools?

Conventional screening models rely almost exclusively on chronological age and self-reported pack-year smoking metrics. In contrast, the CPH-Lung model combines clinical variables with objective, circulating biochemical biomarkers measured from routine blood draws. Consequently, this multi-modal tool detects subclinical inflammatory processes and metabolic alterations. This approach dramatically enhances risk prediction accuracy and identifies vulnerable individuals whom conventional guideline algorithms routinely overlook.

Why does the CPH-Lung model demonstrate higher sensitivity in women?

Women frequently develop lung adenocarcinoma despite having lower cumulative tobacco exposure than men. Because conventional calculators heavily weigh total pack-years, they consistently fail to identify high-risk female candidates for screening. However, CPH-Lung incorporates systemic biochemical signals that reflect individual biological vulnerability rather than smoking duration alone. Therefore, the model achieved a remarkable 57.6% sensitivity in women, successfully overcoming systemic sex-related screening disparities.

Can blood test risk models replace low-dose computed tomography?

No, the CPH-Lung model does not replace low-dose computed tomography imaging. Instead, it serves as an intelligent pre-screening triaging mechanism to determine who truly needs radiologic evaluation. By accurately categorizing six-year personal oncologic risk, the blood-informed algorithm directs imaging resources toward patients with the highest probability of developing malignant lesions. Consequently, this tiered strategy reduces unnecessary radiation exposure while maximizing the diagnostic yield of computed tomography.

Disclaimer: This content is for informational and educational purposes only and should not be taken as professional medical advice. Always seek the advice of a qualified healthcare provider with any questions you may have regarding a medical condition or treatment. Refer to the latest local and national guidelines for clinical practice.

References

Skov-Jeppesen SM et al. Development and Validation of a Blood Test Informed Risk Prediction Model for Lung Cancer-The Copenhagen Lung Cancer Risk Model (CPH-Lung). J Clin Oncol. 2026 Oct 12. doi: 10.1200/JCO-25-02326. PMID: 42863103.

Tammemägi MC, Katki HA, Hocking WG, et al. Selection presets for lung cancer screening: the PLCOm2012 risk prediction model. N Engl J Med. 2013;368(8):728-736.

de Koning HJ, van der Aalst CM, de Jong PA, et al. Reduced lung-cancer mortality with volume CT screening in a randomized trial. N Engl J Med. 2020;382(6):503-513.

National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365(5):395-409.